KR20020012315A - Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법 - Google Patents

Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법 Download PDF

Info

Publication number
KR20020012315A
KR20020012315A KR1020027000609A KR20027000609A KR20020012315A KR 20020012315 A KR20020012315 A KR 20020012315A KR 1020027000609 A KR1020027000609 A KR 1020027000609A KR 20027000609 A KR20027000609 A KR 20027000609A KR 20020012315 A KR20020012315 A KR 20020012315A
Authority
KR
South Korea
Prior art keywords
phenylamino
iodo
methyl
benzamide
difluoro
Prior art date
Application number
KR1020027000609A
Other languages
English (en)
Korean (ko)
Inventor
딕슨알리스테어
리케빈
핀녹로버트덴함
Original Assignee
로즈 암스트롱, 크리스틴 에이. 트러트웨인
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로즈 암스트롱, 크리스틴 에이. 트러트웨인, 워너-램버트 캄파니 filed Critical 로즈 암스트롱, 크리스틴 에이. 트러트웨인
Publication of KR20020012315A publication Critical patent/KR20020012315A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
KR1020027000609A 1999-07-16 2000-07-05 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법 KR20020012315A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14429299P 1999-07-16 1999-07-16
US60/144,292 1999-07-16
PCT/US2000/018347 WO2001005392A2 (fr) 1999-07-16 2000-07-05 Traitement des douleurs chroniques par des inhibiteurs de mek

Publications (1)

Publication Number Publication Date
KR20020012315A true KR20020012315A (ko) 2002-02-15

Family

ID=22507940

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027000609A KR20020012315A (ko) 1999-07-16 2000-07-05 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법

Country Status (16)

Country Link
EP (1) EP1202726A2 (fr)
JP (1) JP2003504400A (fr)
KR (1) KR20020012315A (fr)
CN (1) CN1373660A (fr)
AR (1) AR024732A1 (fr)
AU (1) AU5786000A (fr)
CA (1) CA2374052A1 (fr)
CO (1) CO5300398A1 (fr)
HU (1) HUP0202623A3 (fr)
IL (1) IL147619A0 (fr)
NZ (1) NZ515567A (fr)
PE (1) PE20010545A1 (fr)
PL (1) PL352684A1 (fr)
TR (1) TR200200082T2 (fr)
WO (1) WO2001005392A2 (fr)
ZA (1) ZA200109907B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1301472T3 (da) 2000-07-19 2014-04-07 Warner Lambert Co Oxygenerede estere af 4-iod-phenylamino-benzhydroxamsyrer
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
KR100984613B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
DE602004023207D1 (de) 2003-07-24 2009-10-29 Warner Lambert Co Benzimidazol-derivate als mek-hemmer
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005035493A1 (fr) * 2003-10-08 2005-04-21 Teijin Pharma Limited Methode de production d'un derive d'aminopyrrolidine et d'un compose intermediaire
NZ546011A (en) 2003-10-21 2009-09-25 Warner Lambert Co Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
EP1689387B1 (fr) 2003-11-19 2011-09-14 Array Biopharma, Inc. Inhibiteurs bicycliques de mek et leurs procedes de production
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
RU2006121990A (ru) 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
MY144232A (en) * 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
ES2405785T3 (es) 2005-05-18 2013-06-03 Array Biopharma Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
BRPI0617165B1 (pt) 2005-10-07 2023-10-03 Exelixis Inc Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AU2007269052B2 (en) 2006-07-06 2014-10-23 Array Biopharma Inc. Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors
DK2054418T3 (da) 2006-07-06 2012-02-27 Array Biopharma Inc Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
CN101511842B (zh) 2006-07-06 2012-10-31 阵列生物制药公司 作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶
CA2671982C (fr) 2006-12-14 2016-01-26 Exelixis, Inc. Procedes d'utilisation d'inhibiteurs de mek
ES2533557T3 (es) 2007-07-05 2015-04-13 Array Biopharma, Inc. Pirimidil ciclopentanos como inhibidores de proteína cinasa AKT
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR20150089099A (ko) 2007-07-05 2015-08-04 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
CN101868443A (zh) 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
DK2229391T3 (da) 2007-12-19 2014-10-13 Cancer Res Inst Royal Pyrido[2,3-B]pyrazin-8-substituerede forbindelser og deres anvendelse
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
NZ586346A (en) 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
ES2399384T3 (es) 2008-11-10 2013-04-01 Bayer Schering Pharma Ag Sulfonamido fenoxibenzamidas sustituidas
CA2777430A1 (fr) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Benzosulfonamides substitues
JP2013508320A (ja) 2009-10-21 2013-03-07 バイエル・ファルマ・アクチェンゲゼルシャフト 置換されたハロフェノキシベンズアミド誘導体
JP2013508318A (ja) 2009-10-21 2013-03-07 バイエル・ファルマ・アクチェンゲゼルシャフト 置換されたベンゾスルホンアミド誘導体
PL2531502T3 (pl) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-Butylo-2-fenylo-2H-pirazol-3-ilo)-3-[2-fluoro-4-(1-metylo-2-okso-2,3-dihydro-1H-imidazo[4,5-b]pirydyn-7-yloksy)-fenylo]-mocznik i związki pokrewne oraz ich zastosowanie w terapii
EP2632899A1 (fr) 2010-10-29 2013-09-04 Bayer Intellectual Property GmbH Phénoxypyridines substituées
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
CN104586861A (zh) 2011-04-01 2015-05-06 基因泰克公司 Akt抑制剂化合物和阿比特龙的组合及使用方法
GEP201706690B (en) 2012-10-12 2017-06-26 Exelixis Inc Novel process for making compounds for use in treatment of cancer
AU2014318748B2 (en) * 2013-09-11 2019-02-28 Duquesne University Of The Holy Ghost Novel anthranilic amides and the use thereof
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
WO2017075192A1 (fr) * 2015-10-27 2017-05-04 Acetylon Pharmaceuticals, Inc. Inhibiteurs d'hdac pour le traitement de la neuropathie périphérique diabétique
EA202090693A1 (ru) * 2017-10-17 2020-10-19 Атрива Терапьютикс Гмбх Новый ингибитор mek для лечения вирусных и бактериальных инфекций
EP3989957A1 (fr) * 2019-06-28 2022-05-04 University of Copenhagen Traitement de troubles du snc avec troubles du sommeil

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
ATE344791T1 (de) * 1997-07-01 2006-11-15 Warner Lambert Co 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
ATE277895T1 (de) * 1997-07-01 2004-10-15 Warner Lambert Co 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
HUP0104693A3 (en) * 1998-12-16 2003-12-29 Warner Lambert Co Treatment of arthritis with mek inhibitors

Also Published As

Publication number Publication date
AU5786000A (en) 2001-02-05
HUP0202623A2 (hu) 2002-11-28
TR200200082T2 (tr) 2002-04-22
WO2001005392A3 (fr) 2001-07-19
HUP0202623A3 (en) 2003-03-28
IL147619A0 (en) 2002-08-14
CN1373660A (zh) 2002-10-09
ZA200109907B (en) 2003-02-28
JP2003504400A (ja) 2003-02-04
PE20010545A1 (es) 2001-06-04
CO5300398A1 (es) 2003-07-31
PL352684A1 (en) 2003-09-08
EP1202726A2 (fr) 2002-05-08
NZ515567A (en) 2004-03-26
CA2374052A1 (fr) 2001-01-25
AR024732A1 (es) 2002-10-23
WO2001005392A2 (fr) 2001-01-25

Similar Documents

Publication Publication Date Title
KR20020012315A (ko) Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
DE60005688T2 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
KR20020015376A (ko) Ｍｅｋ 억제제를 사용한 만성 통증의 치료 방법
JP2003504399A (ja) Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
DE69928286T2 (de) Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
DE69928697T2 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
DE69926914T2 (de) 1-heterozyklus-substituierte diarylaminen
JP2003527379A (ja) Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
JP2002534491A (ja) 選択的ｍｅｋ阻害剤としての４−アリールアミノ、４−アリールオキシ、及び４−アリールチオジアリールアミン及びそれらの誘導体
CA2421502A1 (fr) Methode de traitement des allergies
US7030119B1 (en) Method for treating chronic pain using MEK inhibitors
JP2000212141A (ja) ジアリ―ルアミン
JP2004503535A (ja) インドールおよびベンゾイミダゾール１５−リポキシゲナーゼ阻害剤
JP2001055376A (ja) ジアリールアミン
JP2000212157A (ja) ジアリ―ルアミン
ZA200109909B (en) Method for treating chronic pain using MEK inhibitors.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid